Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3944592 | 0.88 | MAPT (0.40) | HTR2CKDM4EMEN1MAPTKMT2A | |
| SCHEMBL3240446 | 0.74 | ACHE (0.46) | GAAHTR2CALDH1A1KDM4EMAPT | |
| SCHEMBL3240735 | 0.74 | ACHE (0.46) | GAAHTR2CALDH1A1KDM4EMAPT | |
| SCHEMBL17144891 | 0.73 | KDM4E (0.36) | HTR2CKDM4EMEN1MAPTKMT2A | |
| SCHEMBL9573206 | 0.72 | ALDH1A1 (0.44) | HTR2CALDH1A1KDM4EMAPTKMT2A | |
| SCHEMBL30042609 | 0.68 | HTR2C (0.41) | HTR2C | |
| SCHEMBL30336885 | 0.67 | DRD2 (0.39) | GAAHTR2CALDH1A1KDM4E | |
| SCHEMBL251439 | 0.66 | MAOA (0.47) | GAAALDH1A1KDM4EMAPT | |
| SCHEMBL31268130 | 0.66 | MAOA (0.47) | GAAALDH1A1KDM4EMAPT | |
| SCHEMBL17144907 | 0.66 | MAOA (0.47) | GAAALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101941977-A | The antitumoral analogue of stratiform element | PHARMA MAR SAU | 2011-01-12 | — | — | CN | disclosed |
| EP-1551844-B1 | ANTITUMORAL ANALOGS OF LAMELLARINS | PHARMA MAR SAU (ES) | 2010-07-28 | — | — | EP | disclosed |
| EP-2138496-A1 | Antitumoral analogs of lamellarins | Pharma Mar, S.A.U. (ES) | 2009-12-30 | — | — | EP | disclosed |
| US-7557118-B2 | Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2009-07-07 | — | — | US | disclosed |
| US-7396837-B2 | Antitumoral analogs of lamellarins | PHARMA MAR, S.A.U. (ES) | 2008-07-08 | — | — | US | disclosed |
| CN-1325476-C | Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, noval compounds thereof and their use as chemotherapeutic agents | UNIV AUSTRALIAN (AU) | 2007-07-11 | — | — | CN | disclosed |
| US-7122673-B2 | Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2006-10-17 | — | — | US | disclosed |
| US-20060173030-A1 | Antitumoral analogs of lamellarins | PHARMA MAR, S.A.U. (ES) | 2006-08-03 | — | — | US | disclosed |
| EP-1621533-A1 | Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2006-02-01 | — | — | EP | disclosed |
| EP-0981517-B1 | PREPARATION OF FUSED POLYCYCLIC ALKALOIDS BY RING CLOSURE OF AZOMETHINE YLIDES | UNIV AUSTRALIAN (AU) | 2005-11-16 | — | — | EP | disclosed |
| US-20050154004-A1 | Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents | AUSTRALIAN NATIONAL UNIVERSITY, THE (AU) | 2005-07-14 | — | — | US | disclosed |
| EP-1551844-A2 | ANTITUMORAL ANALOGS OF LAMELLARINS | Pharma Mar, S.A.U. (ES) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004014917-A2 | ANTITUMORAL ANALOGS OF LAMELLARINS | PHARMA MAR, S.A.U. (ES) | 2004-02-19 | — | — | WO | disclosed |
| US-20030208076-A1 | Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents | AUSTRALIAN NATIONAL UNIVERSITY, THE (AU) | 2003-11-06 | — | — | US | disclosed |
| US-6521757-B1 | Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2003-02-18 | — | — | US | disclosed |
| EP-0981517-A4 | PREPARATION OF FUSED POLYCYCLIC ALKALOIDS BY RING CLOSURE OF AZOMETHINE YLIDES, NOVEL COMPOUNDS THEREOF AND THEIR USE AS CHEMOTHERAPEUTIC AGENTS | UNIV AUSTRALIAN (AU) | 2001-01-24 | — | — | EP | disclosed |
| CN-1262677-A | Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents | UNIV AUSTRALIAN (AU) | 2000-08-09 | — | — | CN | disclosed |
| EP-0981517-A1 | PREPARATION OF FUSED POLYCYCLIC ALKALOIDS BY RING CLOSURE OF AZOMETHINE YLIDES, NOVEL COMPOUNDS THEREOF AND THEIR USE AS CHEMOTHERAPEUTIC AGENTS | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2000-03-01 | — | — | EP | disclosed |
| WO-1998050365-A9 | PREPARATION OF FUSED POLYCYCLIC ALKALOIDS BY RING CLOSURE OF AZOMETHINE YLIDES, NOVEL COMPOUNDS THEREOF AND THEIR USE AS CHEMOTHERAPEUTIC AGENTS | UNIV AUSTRALIAN (AU) | 2000-02-03 | — | — | WO | disclosed |
| WO-1998050365-A1 | PREPARATION OF FUSED POLYCYCLIC ALKALOIDS BY RING CLOSURE OF AZOMETHINE YLIDES, NOVEL COMPOUNDS THEREOF AND THEIR USE AS CHEMOTHERAPEUTIC AGENTS | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173030-A1 | Antitumoral analogs of lamellarins | PLIN3, LPAR3, LPAR2 | GAA 3947/4885HTR2C 3229/4885ALOX5 1392/4885 |
| US-20030208076-A1 | Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents | HCCS, CYCS, CCNO | GAA 3208/4885HTR2C 1214/4885ALOX5 524/4885 |
| US-20050154004-A1 | Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents | HCCS, CYCS, CCNO | GAA 2786/4885HTR2C 1359/4885ALOX5 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.